synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.carbamazepineSerious - Use Alternative (1)carbamazepine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.carbinoxamineMonitor Closely (1)carbinoxamine and triazolam both increase sedation. Use Caution/Monitor.carisoprodolMonitor Closely (1)triazolam and carisoprodol both increase sedation. Use Caution/Monitor.cenobamateMonitor Closely (1)cenobamate, triazolam. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydrateMonitor Closely (1)triazolam and chloral hydrate both increase sedation. Use Caution/Monitor.chloramphenicolContraindicated (1)chloramphenicol will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.chlordiazepoxideMonitor Closely (1)chlordiazepoxide and triazolam both increase sedation. Use Caution/Monitor.chlorpheniramineMonitor Closely (1)chlorpheniramine and triazolam both increase sedation. Use Caution/Monitor.chlorpromazineMonitor Closely (1)triazolam and chlorpromazine both increase sedation. Use Caution/Monitor.chlorzoxazoneMonitor Closely (1)triazolam and chlorzoxazone both increase sedation. Use Caution/Monitor.cilostazolMinor (1)triazolam increases levels of cilostazol by decreasing metabolism. Minor/Significance Unknown.cimetidineSerious - Use Alternative (1)cimetidine will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.cinnarizineMonitor Closely (1)cinnarizine and triazolam both increase sedation. Use Caution/Monitor.ciprofloxacinMinor (1)ciprofloxacin increases levels of triazolam by decreasing metabolism. Minor/Significance Unknown.clarithromycinSerious - Use Alternative (1)clarithromycin will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clemastineMonitor Closely (1)clemastine and triazolam both increase sedation. Use Caution/Monitor.clobazamMonitor Closely (1)triazolam, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineMonitor Closely (1)triazolam and clomipramine both increase sedation. Use Caution/Monitor.clonazepamMonitor Closely (1)clonazepam and triazolam both increase sedation. Use Caution/Monitor.clonidineMonitor Closely (1)clonidine, triazolam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects.clorazepateMonitor Closely (1)clorazepate and triazolam both increase sedation. Use Caution/Monitor.clozapineMonitor Closely (1)triazolam and clozapine both increase sedation. Use Caution/Monitor.cobicistatContraindicated (1)cobicistat will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Triazolam and midazolam (PO) are extensively metabolized by CYP3A. Coadministration of triazolam or midazolam (PO) may cause large increases in the concentrations of these benzodiazepines. Potential for serious and/or life-threatening events (eg, prolonged or increased sedation or respiratory depression).codeineMonitor Closely (1)triazolam and codeine both increase sedation. Use Caution/Monitor.conivaptanMonitor Closely (1)conivaptan will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cortisoneMonitor Closely (1)cortisone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.crizotinibMonitor Closely (1)crizotinib increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crofelemerMonitor Closely (1)crofelemer increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.cyclizineMonitor Closely (1)cyclizine and triazolam both increase sedation. Use Caution/Monitor.cyclobenzaprineMonitor Closely (1)triazolam and cyclobenzaprine both increase sedation. Use Caution/Monitor.cyclophosphamideMinor (1)cyclophosphamide will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.cyclosporineMonitor Closely (1)cyclosporine will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cyproheptadineMonitor Closely (1)cyproheptadine and triazolam both increase sedation. Use Caution/Monitor.dabrafenibMonitor Closely (1)dabrafenib will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.dantroleneMonitor Closely (1)triazolam and dantrolene both increase sedation. Use Caution/Monitor.daridorexantMonitor Closely (1)triazolam and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacinMonitor Closely (1)darifenacin will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.darunavirContraindicated (1)darunavir will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Triazolam and midazolam (PO) are extensively metabolized by CYP3A. Coadministration of triazolam or midazolam (PO) with darunavir/ritonavir may cause large increases in the concentrations of these benzodiazepines. Potential for serious and/or life-threatening events (eg, prolonged or increased sedation or respiratory depression)dasatinibMonitor Closely (1)dasatinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.deferasiroxMonitor Closely (1)deferasirox will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.desfluraneMonitor Closely (1)desflurane and triazolam both increase sedation. Use Caution/Monitor.desipramineMonitor Closely (1)triazolam and desipramine both increase sedation. Use Caution/Monitor.deutetrabenazineMonitor Closely (1)triazolam and deutetrabenazine both increase sedation. Use Caution/Monitor.dexamethasoneMonitor Closely (1)dexamethasone will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dexchlorpheniramineMonitor Closely (1)dexchlorpheniramine and triazolam both increase sedation. Use Caution/Monitor.dexfenfluramineMonitor Closely (1)triazolam increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidineMonitor Closely (1)triazolam and dexmedetomidine both increase sedation. Use Caution/Monitor.dexmethylphenidateMonitor Closely (1)triazolam increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetamineMonitor Closely (1)triazolam increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextromoramideMonitor Closely (1)triazolam and dextromoramide both increase sedation. Use Caution/Monitor.DHEA, herbalMonitor Closely (1)DHEA, herbal will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.diamorphineMonitor Closely (1)triazolam and diamorphine both increase sedation. Use Caution/Monitor.diazepamMonitor Closely (1)diazepam and triazolam both increase sedation. Use Caution/Monitor.diazepam intranasalMonitor Closely (1)diazepam intranasal, triazolam. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.diethylpropionMonitor Closely (1)triazolam increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalinMonitor Closely (1)difelikefalin and triazolam both increase sedation. Use Caution/Monitor.difenoxin hclMonitor Closely (1)triazolam and difenoxin hcl both increase sedation. Use Caution/Monitor.diltiazemMonitor Closely (1)diltiazem will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dimenhydrinateMonitor Closely (1)dimenhydrinate and triazolam both increase sedation. Use Caution/Monitor.diphenhydramineMonitor Closely (1)diphenhydramine and triazolam both increase sedation. Use Caution/Monitor.diphenoxylate hclMonitor Closely (1)triazolam and diphenoxylate hcl both increase sedation. Use Caution/Monitor.dipipanoneMonitor Closely (1)triazolam and dipipanone both increase sedation. Use Caution/Monitor.disulfiramMonitor Closely (1)disulfiram increases levels of triazolam by decreasing metabolism. Use Caution/Monitor.dobutamineMonitor Closely (1)triazolam increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopamineMonitor Closely (1)triazolam increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexamineMonitor Closely (1)triazolam increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinMonitor Closely (1)triazolam and dosulepin both increase sedation. Use Caution/Monitor.doxepinMonitor Closely (1)triazolam and doxepin both increase sedation. Use Caution/Monitor.doxylamineMonitor Closely (1)triazolam and doxylamine both increase sedation. Use Caution/Monitor.dronedaroneMonitor Closely (1)dronedarone will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.droperidolMonitor Closely (1)triazolam and droperidol both increase sedation. Use Caution/Monitor.duvelisibMonitor Closely (1)duvelisib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.efavirenzMonitor Closely (1)efavirenz will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)efavirenz increases levels of triazolam by decreasing metabolism. Contraindicated.elagolixMonitor Closely (1)elagolix decreases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eluxadolineMonitor Closely (1)eluxadoline increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution when CYP3A substrates that have a narrow therapeutic index are coadministered with eluxadoline.elvitegravir/cobicistat/emtricitabine/tenofovir DFMonitor Closely (1)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; consider benzodiazepine dose reduction.encorafenibMonitor Closely (1)encorafenib, triazolam. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.enzalutamideMonitor Closely (1)enzalutamide will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.epcoritamabMonitor Closely (1)epcoritamab, triazolam. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Epcoritamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .ephedrineMonitor Closely (1)triazolam increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrineMonitor Closely (1)triazolam increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrine racemicMonitor Closely (1)triazolam increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.erdafitinibSerious - Use Alternative (1)erdafitinib, triazolam. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with erdafitinib and sensitive CYP3A4 substrates with narrow therapeutic indices. Erdafitinib may altered plasma concentrations of CYP3A4 substrates, leading to either loss of activity or increased toxicity of the substrate.erythromycin baseSerious - Use Alternative (1)erythromycin base will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin ethylsuccinateSerious - Use Alternative (1)erythromycin ethylsuccinate will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin lactobionateSerious - Use Alternative (1)erythromycin lactobionate will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin stearateSerious - Use Alternative (1)erythromycin stearate will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.esketamine intranasalMonitor Closely (1)esketamine intranasal, triazolam. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateMonitor Closely (1)eslicarbazepine acetate will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.esomeprazoleMinor (1)esomeprazole increases levels of triazolam by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.estazolamMonitor Closely (1)estazolam and triazolam both increase sedation. Use Caution/Monitor.ethanolMonitor Closely (1)triazolam and ethanol both increase sedation. Use Caution/Monitor.ethinylestradiolMonitor Closely (1)ethinylestradiol will increase the level or effect of triazolam by Mechanism: decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines.etomidateMonitor Closely (1)etomidate and triazolam both increase sedation. Use Caution/Monitor.etravirineMonitor Closely (1)etravirine will decrease the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.eucalyptusMinor (1)triazolam and eucalyptus both increase sedation. Minor/Significance Unknown.fedratinibMonitor Closely (1)fedratinib will increase the level or effect of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fenfluramineMonitor Closely (1)triazolam increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fentanylSerious - Use Alternative (1)fentanyl, triazolam. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl intranasalSerious - Use Alternative (1)fentanyl intranasal, triazolam. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transdermalSerious - Use Alternative (1)fentanyl transdermal, triazolam. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transmucosalSerious - Use Alternative (1)fentanyl transmucosal, triazolam. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.ferric maltolMonitor Closely (1)ferric maltol, triazolam. Either increases levels of the other by unspecified